Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 8, 22 | -0.82
Increased by
+8.89%
|
-0.78
Decreased by
-5.13%
|
Aug 8, 22 | 0.18
Increased by
+119.78%
|
-0.93
Increased by
+119.35%
|
May 5, 22 | -0.87
Decreased by
-1.16%
|
-0.98
Increased by
+11.22%
|
Feb 28, 22 | -0.96
Decreased by
-1.05%
|
-0.69
Decreased by
-39.13%
|
Nov 4, 21 | -0.90
Increased by
+2.17%
|
-0.94
Increased by
+4.26%
|
Aug 9, 21 | -0.91
Increased by
+20.18%
|
-0.89
Decreased by
-2.25%
|
May 4, 21 | -0.86
Increased by
+28.33%
|
-0.92
Increased by
+6.52%
|
Mar 1, 21 | -0.95
Increased by
+30.15%
|
-0.74
Decreased by
-28.38%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 4.46 M
Decreased by
-16.96%
|
-84.09 M
Increased by
+0.68%
|
Decreased by
-1.89 K%
Decreased by
-19.62%
|
Jun 30, 22 | 51.58 M
Increased by
+1.23 K%
|
18.47 M
Increased by
+122.04%
|
Increased by
+35.80%
Increased by
+101.65%
|
Mar 31, 22 | 7.31 M
Increased by
+105.91%
|
-88.11 M
Decreased by
-12.47%
|
Decreased by
-1.20 K%
Increased by
+45.38%
|
Dec 31, 21 | 7.55 M
Increased by
+N/A%
|
-93.35 M
Decreased by
-14.81%
|
Decreased by
-1.24 K%
Decreased by
N/A%
|
Sep 30, 21 | 5.37 M
Increased by
+N/A%
|
-84.66 M
Decreased by
-13.88%
|
Decreased by
-1.58 K%
Decreased by
N/A%
|
Jun 30, 21 | 3.87 M
Increased by
+N/A%
|
-83.79 M
Decreased by
-8.18%
|
Decreased by
-2.17 K%
Decreased by
N/A%
|
Mar 31, 21 | 3.55 M
Increased by
+N/A%
|
-78.33 M
Decreased by
-6.57%
|
Decreased by
-2.21 K%
Decreased by
N/A%
|
Dec 31, 20 | 0.00
Decreased by
N/A%
|
-81.31 M
Decreased by
-3.58%
|
Decreased by
N/A%
Decreased by
N/A%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.